Tanshinone IIA enhances susceptibility of non-small cell lung cancer cells to NK cell-mediated lysis by up-regulating ULBP1 and DR5.
Abietanes
/ pharmacology
Animals
Antineoplastic Agents, Phytogenic
/ pharmacology
Biomarkers
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cytotoxicity, Immunologic
/ drug effects
Disease Models, Animal
GPI-Linked Proteins
/ genetics
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Intracellular Signaling Peptides and Proteins
/ genetics
Killer Cells, Natural
/ drug effects
Lung Neoplasms
Mice
Receptors, TNF-Related Apoptosis-Inducing Ligand
/ genetics
Xenograft Model Antitumor Assays
DR5
ER stress
NK cells
Tanshinone IIA
ULBP1
non-small cell lung cancer
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
08
04
2021
received:
24
11
2021
accepted:
09
04
2021
pubmed:
29
4
2021
medline:
31
8
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
Natural killer (NK) cells have a great potential in cancer immunotherapy. However, their therapeutic efficacy is clinically limited owing to cancer cell immune escape. Therefore, it is urgently necessary to develop novel method to improve the antitumor immunity of NK cells. In the present study, it was found that the natural product tanshinone IIA (TIIA) enhanced NK cell-mediated killing of non-small cell lung cancer (NSCLC) cells. TIIA in combination with adoptive transfer of NK cells synergistically suppressed the tumor growth of NSCLC cells in an immune-incompetent mouse model. Furthermore, TIIA significantly inhibited the tumor growth of Lewis lung cancer (LLC) in an immune-competent syngeneic mouse model, and such inhibitory effect was reversed by the depletion of NK cells. Moreover, TIIA increased expressions of ULBP1 and DR5 in NSCLC cells, and inhibition of DR5 and ULBP1 reduced the enhancement of NK cell-mediated lysis by TIIA. Besides, TIIA increased the levels of p-PERK, ATF4 and CHOP. Knockdown of ATF4 completely reversed the up-regulation of ULBP1 and DR5 by TIIA in all detected NSCLC cells, while knockdown of CHOP only partly reduced these enhanced expressions in small parts of NSCLC cells. These results demonstrated that TIIA could increase the susceptibility of NSCLC cells to NK cell-mediated lysis by up-regulating ULBP1 and DR5, suggesting that TIIA had a promising potential in cancer immunotherapy, especially in NK cell-based cancer immunotherapy.
Identifiants
pubmed: 33909909
doi: 10.1002/JLB.5MA1120-776RR
doi:
Substances chimiques
Abietanes
0
Antineoplastic Agents, Phytogenic
0
Biomarkers
0
GPI-Linked Proteins
0
Intracellular Signaling Peptides and Proteins
0
Receptors, TNF-Related Apoptosis-Inducing Ligand
0
TNFRSF10B protein, human
0
ULBP1 protein, human
0
tanshinone
03UUH3J385
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-325Informations de copyright
©2021 Society for Leukocyte Biology.
Références
Trabanelli S, Gomez-Cadena A, Salomé B, et al. Human innate lymphoid cells (ILCs): toward a uniform immune-phenotyping. Cytometry B Clin Cytom. 2018;94:392-399.
Di Vito C, Mikulak J, Zaghi E, et al. NK cells to cure cancer. Semin Immunol. 2019.
Chiossone L, Dumas PY, Vienne M, et al. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671-688.
Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105:1319-1329.
Carrega P, Ferlazzo G. Natural Killers Are Made Not Born: how to Exploit NK Cells in Lung Malignancies. Front Immunol. 2017;8:277.
Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17:1025-36.
Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends Immunol. 2019;40:142-158.
Nayyar G, Chu Y, Cairo MS. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Front Oncol. 2019;9:51.
Grudzien M, Rapak A. Effect of Natural Compounds on NK Cell Activation. J Immunol Res. 2018;2018:4868417.
Yao C, Ni Z, Gong C, et al. Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. Autophagy. 2018;14:1831-1844.
Gong C, Yao C, Xu Z, et al. Enhancement of NK cell-mediated lysis of non-small lung cancer cells by nPKC activator, ingenol 3,20 dibenzoate. Mol Immunol. 2017;83:23-32.
Zhang X, Zhou Y, Gu YE. Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways. Oncol Lett. 2019;17:1896-1902.
Lv C, Zeng H-W, Wang J-X, et al. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Cell Death Dis. 2018;9:165.
Yen JH, Huang S-T, Huang H-S, et al. HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone IIA in human osteosarcoma cells. Cell Death Dis. 2018;9:1003.
Sui H, Zhao J, Zhou L, et al. Tanshinone IIA inhibits beta-catenin/VEGF-mediated angiogenesis by targeting TGF-beta1 in normoxic and HIF-1alpha in hypoxic microenvironments in human colorectal cancer. Cancer Lett. 2017;403:86-97.
Wang X, Lee DA, Wang Y, et al. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin Exp Immunol. 2013;172:104-12.
Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15-22.
Pan TL, Wang P-W, Hung Y-C, et al. Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. Proteomics. 2013;13:3411-23.
Yoon MJ, Kang YJ, Kim IY, et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis. 2013;34:1918-28.
Hosomi S, Grootjans J, Huang Y-H, et al. New Insights Into the Regulation of Natural-Killer Group 2 Member D (NKG2D) and NKG2D-Ligands: endoplasmic Reticulum Stress and CEA-Related Cell Adhesion Molecule 1. Front Immunol. 2018;9:1324.
Huang ST, Huang C-C, Huang W-L, et al. Tanshinone IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro associated with mitochondrial dysfunction. Sci Rep. 2017;7:40382.
Zhang Y, Wei R-X, Zhu X-B, et al. Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro. Anticancer Drugs. 2012;23:212-9.
Won SH, Lee H-J, Jeong S-J, et al. Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. Biol Pharm Bull. 2010;33:1828-34.
Kim EO, Kang SE, Im CR, et al. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction. Int J Oncol. 2016;48:2205-12.
Gowen BG, Chim B, Marceau CD, et al. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife. 2015.
Hosomi S, Grootjans J, Tschurtschenthaler M, et al. Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation. J Exp Med. 2017;214:2985-2997.
Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74.
Terry S, Abdou A, Engelsen AST, et al. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. Cancer Immunol Res. 2019;7:1789-1802.